Natera, Inc. (NTRA) Stock

About Natera, Inc.

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Natera, Inc. is led by CEO Steven Leonard Chapman, employs 4,424 people, headquartered in Austin, US, publicly traded since 2015.

Natera, Inc. (NTRA) stock trades at $258.03 with a market capitalization of $36.95B. The stock is valued at a price-to-earnings (P/E) ratio of -299.78, price-to-book of 15.85, price-to-sales of 10.67. Over the past 52 weeks the stock has ranged between $131.81 and $286.80, and currently trades 10.0% below its 52-week high.

On profitability, Natera, Inc. generates a return on equity (ROE) of -15.02%, return on capital employed of -18.11%, an operating margin of -13.44%, a net profit margin of -9.05%.

In its most recent fiscal year, Natera, Inc. reported annual revenue of $2.3B, net profit of $-208.0M, revenue has compounded at 42.6% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.14 — a conservative balance sheet with little leverage risk, a current ratio of 3.39, total assets of $2.4B, $466.0M in cash and equivalents.

NTRA has an average daily trading volume of 1,500,000 shares, a beta of 1.54 (more volatile than the overall market).

Official website: www.natera.com